Anteris Technologies, a heart medtech company backed by both L1 Capital and New York-based hedge fund Sio Partners, has successfully raised approximately $38.5 million through a recent capital raising initiative. This funding effort, which initially aimed for $30 million, was expanded due to significant investor demand.
The placement, launched on September 29, 2023, offered new chess depositary interests listed on the Australian Securities Exchange (ASX) at a price of $7.50 per share. This represents a 14.8 percent discount to the company’s last closing price. The capital raise was managed solely by Evolution Capital, as noted in a term sheet.
Innovative Heart Valve Technology Under Development
Headquartered in Minneapolis and founded in Australia, Anteris is focused on advancing its flagship heart valve technology, known as DurAVR. This innovative system is designed to replicate the functionality of a healthy human aortic valve, addressing aortic stenosis, a condition characterized by the narrowing of the valve that impedes blood flow.
Since 2021, Anteris has been conducting clinical trials of the DurAVR prosthetic aortic valve, reporting that 130 patients have been successfully treated to date. The positive outcomes from these trials contribute to the growing confidence in the technology’s potential effectiveness in treating heart valve diseases.
Despite facing challenges that led to its removal from the All Ordinaries index in September 2023, Anteris has shown resilience, with its stock price trending upwards recently. This recovery follows a series of announcements, including a testing and manufacturing agreement with Switchback Medical and a quarterly results update. The company is also preparing to launch its pivotal Paradigm trial later this month, which is anticipated to further validate the DurAVR technology.
Investors are closely watching Anteris, especially given its current market capitalization of approximately $317 million. The company’s strategic initiatives and robust clinical results may position it well for future growth within the competitive heart medtech landscape.
